Isomorphic Labs just raised at $40-50B valuation — that's ~3x the combined market cap of $TEM + $RXRX + $SDGR. Here's what you're actually buying:
The company is basically burning cash with zero revenue. UK filings show £55M from pharma partnerships (booked as "other income"), £190M R&D spend, £159M net loss, 225 headcount. The "assets" are milestone deals: $LLY up to $1.7B, $NVS up to $1.2B, $JNJ signed Jan 2025. Milestones are staged payments IF the drug hits certain phases — it's a ceiling, not actual revenue.
What investors are paying for: Demis Hassabis (2024 Nobel Chemistry, stepped down as DeepMind CEO in Aug to become Alphabet's first Chief Scientist, still CEO of Isomorphic) + AlphaFold 3 platform (co-developed with DeepMind). Alphabet is the controlling shareholder. Funding structure tells the story — Thrive Capital led both rounds, with Alphabet, GV, CapitalG, MGX, Temasek, and UK's sovereign AI fund piling in.
Public market comp check: $MRNA trades at ~$784B market cap with actual products and revenue. At $40-50B, Isomorphic is 2/3 of a Moderna with zero products. It's also ~20x $RXRX ($2.29B), plus $SDGR ($2.04B) + $TEM ($12.69B) combined = $17B. The $50B valuation is 2.9x that entire basket.
AIDD and AI4S have been hot in private markets for 6+ months. If this round closes at $40B+, it sets a new pricing anchor for the entire sector. Public markets should have 6-12 months of runway to catch up to this private valuation reset.
The company is basically burning cash with zero revenue. UK filings show £55M from pharma partnerships (booked as "other income"), £190M R&D spend, £159M net loss, 225 headcount. The "assets" are milestone deals: $LLY up to $1.7B, $NVS up to $1.2B, $JNJ signed Jan 2025. Milestones are staged payments IF the drug hits certain phases — it's a ceiling, not actual revenue.
What investors are paying for: Demis Hassabis (2024 Nobel Chemistry, stepped down as DeepMind CEO in Aug to become Alphabet's first Chief Scientist, still CEO of Isomorphic) + AlphaFold 3 platform (co-developed with DeepMind). Alphabet is the controlling shareholder. Funding structure tells the story — Thrive Capital led both rounds, with Alphabet, GV, CapitalG, MGX, Temasek, and UK's sovereign AI fund piling in.
Public market comp check: $MRNA trades at ~$784B market cap with actual products and revenue. At $40-50B, Isomorphic is 2/3 of a Moderna with zero products. It's also ~20x $RXRX ($2.29B), plus $SDGR ($2.04B) + $TEM ($12.69B) combined = $17B. The $50B valuation is 2.9x that entire basket.
AIDD and AI4S have been hot in private markets for 6+ months. If this round closes at $40B+, it sets a new pricing anchor for the entire sector. Public markets should have 6-12 months of runway to catch up to this private valuation reset.